Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.

Gautier JF, Martinez L, Penfornis A, Eschwège E, Charpentier G, Huret B, Madani S, Gourdy P

Advances in therapy30 Sept 2015Cited by 29 (Europe PMC)

PMID26424330PMCIDPMC4604502DOI10.1007/s12325-015-0245-xPepBankPUB-26424330

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, a minority maintained liraglutide and reached the HbA1c target after 2 years.
In plain wordsIn adults with type 2 diabetes treated in routine care, fewer than a third stayed on liraglutide and reached the HbA1c target after 2 years.
Peptide
Liraglutide
Outcome
Not applicablePatients on liraglutide with HbA1c below 7.0% at 2 years
Study
n = 3,152
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Proportion on liraglutide with HbA1c <7.0%
29.5%
end of study
Source sentences
Summary
At the end of the study, 29.5% of patients maintained liraglutide treatment and reached the HbA(1c) target.
2 context sentences(design, population, supporting numbers)
Summary · context
The primary study endpoint was the proportion of patients still receiving liraglutide and presenting with HbA1c <7.0% after 2 years of follow-up.
Summary · context
This observational, prospective, multicenter study included 3152 adults with type 2 diabetes who had recently started or were about to start liraglutide treatment.
Report a problemFND-2642433001
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, mean HbA1c fell significantly from baseline during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes treated in routine care, HbA1c fell from baseline during liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n = 3,152
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
HbA1c baseline
8.46%
baseline
HbA1c after follow-up
7.44%
end of follow-up
Source sentences
Summary
Mean (±SD) HbA(1c), fasting plasma glucose concentration, body weight and BMI were significantly reduced from baseline [8.46% (±1.46) to 7.44% (±1.20); 180 (±60) to 146 (±44) mg/dL; 95.2 (±20.0) to 91.1 (±19.6) kg; 34.0 (±7.2) to 32.5 (±6.9) kg/m(2); respectively, all P < 0.0001].
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective, multicenter study included 3152 adults with type 2 diabetes who had recently started or were about to start liraglutide treatment.
Report a problemFND-2642433002
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, fasting plasma glucose fell significantly from baseline during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes treated in routine care, fasting blood sugar fell from baseline during liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change
Study
n = 3,152
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Fasting plasma glucose baseline
180 mg/dL
baseline
Fasting plasma glucose after follow-up
146 mg/dL
end of follow-up
Source sentences
Summary
Mean (±SD) HbA(1c), fasting plasma glucose concentration, body weight and BMI were significantly reduced from baseline [8.46% (±1.46) to 7.44% (±1.20); 180 (±60) to 146 (±44) mg/dL; 95.2 (±20.0) to 91.1 (±19.6) kg; 34.0 (±7.2) to 32.5 (±6.9) kg/m(2); respectively, all P < 0.0001].
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective, multicenter study included 3152 adults with type 2 diabetes who had recently started or were about to start liraglutide treatment.
Report a problemFND-2642433003
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, body weight fell significantly from baseline during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes treated in routine care, body weight fell from baseline during liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 3,152
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Body weight baseline
95.2 kg
baseline
Body weight after follow-up
91.1 kg
end of follow-up
Source sentences
Summary
Mean (±SD) HbA(1c), fasting plasma glucose concentration, body weight and BMI were significantly reduced from baseline [8.46% (±1.46) to 7.44% (±1.20); 180 (±60) to 146 (±44) mg/dL; 95.2 (±20.0) to 91.1 (±19.6) kg; 34.0 (±7.2) to 32.5 (±6.9) kg/m(2); respectively, all P < 0.0001].
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective, multicenter study included 3152 adults with type 2 diabetes who had recently started or were about to start liraglutide treatment.
Report a problemFND-2642433004
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, BMI fell significantly from baseline during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes treated in routine care, BMI fell from baseline during liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreaseBMI change
Study
n = 3,152
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
BMI baseline
34 kg/m(2)
baseline
BMI after follow-up
32.5 kg/m(2)
end of follow-up
Source sentences
Summary
Mean (±SD) HbA(1c), fasting plasma glucose concentration, body weight and BMI were significantly reduced from baseline [8.46% (±1.46) to 7.44% (±1.20); 180 (±60) to 146 (±44) mg/dL; 95.2 (±20.0) to 91.1 (±19.6) kg; 34.0 (±7.2) to 32.5 (±6.9) kg/m(2); respectively, all P < 0.0001].
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective, multicenter study included 3152 adults with type 2 diabetes who had recently started or were about to start liraglutide treatment.
Report a problemFND-2642433005
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in routine practice, treatment satisfaction scores rose significantly from baseline during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes treated in routine care, satisfaction with treatment rose from baseline during liraglutide treatment.
Peptide
Liraglutide
Outcome
IncreaseTreatment satisfaction (DTSQs score)
Study
n = 3,152
Outcome group
Quality of life · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
DTSQs score baseline
22.17 points
baseline
DTSQs score after follow-up
28.55 points
end of follow-up
Source sentences
Summary
Patient treatment satisfaction increased, with the mean diabetes treatment satisfaction questionnaire status version score increasing from 22.17 (±7.64) to 28.55 (±5.79), P < 0.0001.
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective, multicenter study included 3152 adults with type 2 diabetes who had recently started or were about to start liraglutide treatment.
Report a problemFND-2642433006
07HumanObservational studySafety outcome
In adults with type 2 diabetes in routine practice, gastrointestinal events were the main adverse event type with liraglutide.
In plain wordsIn adults with type 2 diabetes treated in routine care, stomach and gut problems were the most common side effects of liraglutide.
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal adverse events
Study
n = 3,152
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Frequency of gastrointestinal adverse events
10.9%
all patients
Source sentences
Summary
The main adverse event type was gastrointestinal, with a frequency of 10.9%
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective, multicenter study included 3152 adults with type 2 diabetes who had recently started or were about to start liraglutide treatment.
Report a problemFND-2642433007
08HumanObservational studySafety outcome
In adults with type 2 diabetes in routine practice, the share of patients with at least one hypoglycemic episode decreased during liraglutide treatment.
In plain wordsIn adults with type 2 diabetes treated in routine care, fewer patients had low blood sugar episodes during liraglutide treatment.
Peptide
Liraglutide
Outcome
DecreasePatients with at least one hypoglycemic episode
Study
n = 3,152
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 2 yearsAs given in this study (human).
Measurements
Patients with >=1 hypoglycemic episode
6.9%
before
Patients with >=1 hypoglycemic episode
4.4%
after
Source sentences
Summary
the percentage of patients suffering ≥1 hypoglycemic episode decreased from 6.9% to 4.4%.
1 context sentence(design, population, supporting numbers)
Summary · context
This observational, prospective, multicenter study included 3152 adults with type 2 diabetes who had recently started or were about to start liraglutide treatment.
Report a problemFND-2642433008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT01226966

Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 3,152Sept 2010 to Nov 2013

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 13 Feb 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.